Alternative non-antibody protein scaffolds for molecular imaging of cancer

Current Opinion in Chemical Engineering

Volumn 2, Issue 4, 2013, Pages 425-432

  Stern, Lawrence A ^a   Case, Brett A ^a   Hackel, Benjamin J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; DISEASES; LIGANDS; SCAFFOLDS (BIOLOGY);

ANKYRIN REPEATS; BIODISTRIBUTIONS; CANCER BIOMARKERS; CLINICAL EVALUATION; CONSERVED REGIONS; HIGH-CONTRAST IMAGES; NOVEL DIAGNOSTICS; PROTEIN SCAFFOLDS;

MOLECULAR IMAGING;

EID: 84899980586     PISSN: None     EISSN: 22113398     Source Type: Journal    
DOI: 10.1016/j.coche.2013.08.009     Document Type: Review

References (63)

1. Knowles SM, Wu AM: Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 2012, 30:3884-3892.
2. Schmidt MM, Wittrup KD: A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009, 8:2861-2871.
3. Schottelius M, Wester H-J: Molecular imaging targeting peptide receptors. Methods 2009, 48:161-177.
4. Feldwisch J, Tolmachev V: Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol 2012, 899:103-126.
5. Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Stahl S et al.: Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
6. Orlova A, Tran T, Widström C, Engfeldt T, Eriksson Karlström A, Tolmachev V: Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med 2007, 20:397-404.
7. Tran T, Engfeldt T, Orlova A, Sandstroem M, Feldwisch J, Abrahmsén L, Wennborg A, Tolmachev V, Karlstroem AE: Tc-99m-maEEE-Z(HER2:342), an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 2007, 18:1956-1964. (Pubitemid 350219996)
8. Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J: [18F]FBEM-ZHER2:342 - affibody molecule - a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2007, 35:1008-1018.
9. Orlova A, Rosik D, Sandstrom M, Lundqvist H, Einarsson L, Tolmachev V: Evaluation of [(111/114m)In]CHX-A00-DTPAZHER2: 342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging 2007, 51:314-323. (Pubitemid 350267702)
10. Orlova A, Wallberg H, Stone-Elander S, Tolmachev V: On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009, 50:417-425.
11. Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J: (68)Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging 2011, 38:1967-1976.
12. Wallberg H, Grafström J, Cheng Q, Lu L, Martinsson Ahlzén H-S, Samén E, Thorell J-O, Johansson K, Dunas F, Olofsson MH et al.: HER2-positive tumors imaged within 1 hour using a sitespecifically 11C-labeled Sel-tagged affibody molecule. J Nucl Med 2012, 53:1446-1453.
13. Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J: Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J Nucl Med 2010, 51:892-897.
14. Tolmachev V, Friedman M, Sandström M, Eriksson TLJ, Rosik D, Hodik M, Stahl S, Frejd FY, Orlova A: Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 2009, 50:274-283.
15. Tolmachev V, Rosik D, Wallberg H, Sjöberg A, Sandström M, Hansson M, Wennborg A, Orlova A: Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010, 37:613-622.
16. Nordberg E, Orlova A, Friedman M, Tolmachev V, Stahl S, Nilsson FY, Glimelius B, Carlsson J: In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep 2008, 19:853-857. (Pubitemid 351802651)
17. Miao Z, Ren G, HHongguang L, Jiang L, Cheng Z: Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjug Chem 2010, 21:947-954.
18. Miao Z, Ren G, Liu H, Qi S, Wu S, Cheng Z: PET of EGFR expression with an 18F-labeled affibody molecule. J Nucl Med 2012, 53:1110-1118.
19. Tolmachev V, Malmberg J, Hofström C, Abrahmsén L, Bergman T, Sjöberg A, Sandström M, Gräslund T, Orlova A: Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTAZIGF1R: 4551. J Nucl Med 2012, 53:90-97.
20. Orlova A, Hofström C, Strand J, Varasteh Z, Sandström M, Andersson K, Tolmachev V, Gräslund T: [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur J Nucl Med Mol Imaging 2013, 40:439-449.
21. Honarvar H, Jokilaakso N, Andersson K, Malmberg J, Rosik D, Orlova A, Karlström AE, Tolmachev V, Järver P: Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for in vivo molecular imaging. Nucl Med Biol 2013, 40:378-386.
22. Webster JM, Zhang R, Gambhir SS, Cheng Z, Syud FA: Engineered two-helix small proteins for molecular recognition. ChemBioChem 2009, 10:1293-1296.
23. Ren G, Zhang R, Liu Z, Webster JM, Miao Z, Gambhir SS, Syud FA, Cheng Z: A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J Nucl Med 2009, 50:1492-1499.
24. Miao Z, Ren G, Jiang L, HHongguang L, Webster JM, Zhang R, Namavari M, Gambhir SS, Syud F, Cheng Z: A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor. Eur J Nucl Med Mol Imaging 2011, 38:1977-1984.
25. Rosik D, Orlova A, Malmberg J, Altai M, Varasteh Z, Sandström M, Karlström AE, Tolmachev V: Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. Eur J Nucl Med Mol Imaging 2011, 39:693-702.
26. Moore SJ, Cochran JR: Engineering knottins as novel binding agents. Methods Enzymol 2012, 503:223-251.
27. Kimura RH, Cheng Z, Gambhir SS, Cochran JR: Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 2009, 69:2435-2442.
28. Miao Z, Ren G, HHongguang L, Kimura RH, Jiang L, Cochran JR, Gambhir SS, Cheng Z: An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem 2009, 20:2342-2347.
29. Nielsen CH, Kimura RH, Withofs N, Tran PT, Miao Z, Cochran JR, Cheng Z, Felsher D, Kjær A, Willmann JK et al.: PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. Cancer Res 2010, 70:9022-9030.
30. Kimura RH, Miao Z, Cheng Z, Gambhir SS, Cochran JR: A duallabeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem 2010, 21:436-444.
31. Jiang L, Kimura RH, Miao Z, Silverman AP, Ren G, HHongguang L, Li P, Gambhir SS, Cochran JR, Cheng Z: Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med 2010, 51:251-258.
32. Jiang L, Miao Z, Kimura RH, Silverman AP, Ren G, HHongguang L, Lu H, Cochran JR, Cheng Z: 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis. J Biomed Biotechnol 2012, 2012:368075 (Internet).
33. Jiang H, Moore SJ, Liu S, HHongguang L, Miao Z, Cochran FV, Liu Y, Tian M, Cochran JR, Zhang H et al.: A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging. Amino Acids 2013, 44:673-681.
34. Kimura RH, Teed R, Hackel BJ, Pysz MA, Chuang CZ, Sathirachinda A, Willmann JK, Gambhir SS: Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res 2012, 18:839-849.
35. Hackel BJ, Kimura RH, Miao Z, Liu H, Sathirachinda A, Cheng Z, Chin FT, Gambhir SS: 18F-labeled cystine knot peptides for PET imaging of integrin avb6. J Nucl Med (no date), in press.
36. Moore SJ, Leung CL, Norton HK, Cochran JR: Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging. PLoS ONE 2013, 8:e60498.
37. Lipovsek D: Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 2011, 24:3-9.
38. Chen TF, de Picciotto S, Hackel BJ, Wittrup KD: Engineering fibronectin-based binding proteins by yeast surface display. Methods Enzymol 2013, 523:303-326.
39. Hackel BJ, Kimura RH, Gambhir SS: Use of 64Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging. Radiology 2012, 263:179-188.
40. Hackel BJ, Sathirachinda A, Gambhir SS: Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution. Protein Eng Des Sel 2012, 25:639-647.
41. Tamaskovic R, Simon M, Stefan N, Schwill M, Plückthun A: Designed ankyrin repeat proteins (DARPins) from research to therapy. Methods Enzymol 2012, 503:101-134.
42. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, Dreier B, Schibli R, Binz HK, Waibel R et al.: Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010, 70:1595-1605.
43. Martin-Killias P, Patricia M-K, Stefan N, Rothschild S, Plückthun A, Zangemeister-Wittke U: A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 2011, 17:100-110.
44. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Havlik E, Schima W, Traub-Weidinger T, Graf S, Beheshti M, Schmid M et al.: Iodine-123-vascular endothelial growth factor-165 (123IVEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. Q J Nucl Med Mol Imaging 2004, 48:198-206. (Pubitemid 39485387)
45. Chen K, Cai W, Li Z-B, Wang H, Chen X: Quantitative PET imaging of VEGF receptor expression. Mol Imaging Biol 2008, 11:15-22.
46. Kang CM, Kim S-M, Koo H-J, Yim MS, Lee K-H, Ryu EK, Choe YS: In vivo characterization of 68Ga-NOTA-VEGF121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. Eur J Nucl Med Mol Imaging 2012, 40:198-206.
47. Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, Blankenberg FG, Backer JM: Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGFbased probes. Nat Med 2007, 13:504-509. (Pubitemid 46559824)
48. Eder M, Krivoshein AV, Backer M, Backer JM, Haberkorn U, Eisenhut M: ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature. Nucl Med Biol 2010, 37:405-412.
49. Velikyan I, Sundberg AL, Lindhe O, Höglund AU, Eriksson O, Werner E, Carlsson J, Bergström M, Langström B, Tolmachev V: Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005, 46:1881-1888. (Pubitemid 46196651)
50. Li W, Niu G, Lang L, Guo N, Ma Y, Kiesewetter DO, Backer JM, Shen B, Chen X: PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model. Eur J Nucl Med Mol Imaging 2011, 39:300-308.
51. Guo M-F, Zhao Y, Tian R, Li L, Guo L, Xu F, Liu Y-M, He Y-B, Bai S, Wang J: In vivo 99mTc-HYNIC-annexin V imaging of early tumor apoptosis in mice after single dose irradiation. J Exp Clin Cancer Res 2009, 28:136.
52. Hu S, Kiesewetter DO, Zhu L, Guo N, Gao H, Liu G, Hida N, Lang L, Niu G, Chen X: Longitudinal PET imaging of doxorubicininduced cell death with 18F-Annexin V. Mol Imaging Biol 2012, 14:762-770.
53. Rottey S, Slegers G, Van Belle S, Goethals I, Van de Wiele C: Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med 2006, 47:1813-1818. (Pubitemid 47545004)
54. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
55. Cheng Z, De Jesus OP, Namavari M, De A, Levi J, Webster JM, Zhang R, Lee B, Syud FA, Gambhir SS: Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 2008, 49:804-813. (Pubitemid 351717547)
56. Tolmachev V, Mume E, Sjöberg S, Frejd FY, Orlova A: Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging 2009, 36:692-701.
57. Cheng Z, Jesus OP, Kramer DJ, De A, Webster JM, Gheysens O, Levi J, Namavari M, Wang S, Park JM et al.: 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 2009, 12:316-324.
58. Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L, Orlova A: Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med 2012, 53:953-960.
59. Tran TA, Ekblad T, Orlova A, Sandström M, Feldwisch J, Wennborg A, Abrahmsén L, Tolmachev V, Eriksson Karlström A: Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Bioconjug Chem 2008, 19:2568-2576.
60. Malmberg J, Perols A, Varasteh Z, Altai M, Braun A, Sandström M, Garske U, Tolmachev V, Orlova A, Karlström AE: Comparative evaluation of synthetic anti-HER2 Affibody molecules sitespecifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2012, 39:481-492.
61. Ekblad T, Tran T, Orlova A, Widström C, Feldwisch J, Abrahmsén L, Wennborg A, Karlström AE, Tolmachev V: Development and preclinical characterisation of 99mTclabelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 2008, 35:2245-2255.
62. Engfeldt T, Tran T, Orlova A, Widström C, Feldwisch J, Abrahmsén L, Wennborg A, Karlström AE, Tolmachev V: 99mTcchelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 2007, 34:1843-1853. (Pubitemid 47599054)
63. Perols A, Honarvar H, Strand J, Selvaraju R, Orlova A, Karlström AE, Tolmachev V: Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. Bioconjug Chem 2012, 23:1661-1670.